These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9533760)

  • 1. Goralatide (AcSDKP), a negative growth regulator, protects the stem cell compartment during chemotherapy, enhancing the myelopoietic response to GM-CSF.
    Bogden AE; Moreau JP; Gamba-Vitalo C; Deschamps de Paillette E; Tubiana M; Frindel E; Carde P
    Int J Cancer; 1998 Mar; 76(1):38-46. PubMed ID: 9533760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circadian-based effects of AcSDKP, with or without rhG-CSF on hematologic toxicity of chemotherapy in mice.
    Li XM; Soulard C; Filipski E; Deschamps de Paillette E; Lévi F
    Eur J Haematol; 1998 Mar; 60(3):181-8. PubMed ID: 9548417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Goralatide (AcSDKP) selectively protects murine hematopoietic progenitors and stem cells against hyperthermic damage.
    Wierenga PK; Konings AW
    Exp Hematol; 1996 Feb; 24(2):246-52. PubMed ID: 8641348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.
    Vadhan-Raj S; Broxmeyer HE; Hittelman WN; Papadopoulos NE; Chawla SP; Fenoglio C; Cooper S; Buescher ES; Frenck RW; Holian A
    J Clin Oncol; 1992 Aug; 10(8):1266-77. PubMed ID: 1634916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tetrapeptide AcSDKP reduces the sensitivity of murine CFU-MK and CFU-GM progenitors to aracytine in vitro and in vivo.
    Aidoudi S; Guigon M; Drouet V; Caen JP; Han ZC
    Int J Hematol; 1998 Aug; 68(2):145-55. PubMed ID: 9803673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granulocyte-colony-stimulating factor enhances the circulating hematopoietic progenitors in lung cancer patients treated with cisplatin-containing regimens.
    Mukai J; Shimizu E; Ogura T
    Jpn J Cancer Res; 1992 Jul; 83(7):746-53. PubMed ID: 1381342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity: improvement in mice survival and protection of bone marrow stem cells and progenitors.
    Massé A; Ramirez LH; Bindoula G; Grillon C; Wdzieczak-Bakala J; Raddassi K; Deschamps de Paillette E; Mencia-Huerta JM; Koscielny S; Potier P; Sainteny F; Carde P
    Blood; 1998 Jan; 91(2):441-9. PubMed ID: 9427696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo modifications of AcSDKP metabolism and haematopoiesis in mice treated with 5-fluorouracil and Goralatide.
    Comte L; Lorgeot V; Bignon J; Volkov L; Dupuis F; Wdzieczak-Bakala J; Praloran V
    Eur J Clin Invest; 1998 Oct; 28(10):856-63. PubMed ID: 9793000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of granulopoiesis by transforming growth factor beta: synergy with granulocyte/macrophage-colony-stimulating factor.
    Keller JR; Jacobsen SE; Sill KT; Ellingsworth LR; Ruscetti FW
    Proc Natl Acad Sci U S A; 1991 Aug; 88(16):7190-4. PubMed ID: 1831268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
    Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
    J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation.
    te Boekhorst PA; Löwenberg B; Vlastuin M; Sonneveld P
    Leukemia; 1993 Aug; 7(8):1191-8. PubMed ID: 7688839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased granulopoiesis after sequential administration of transforming growth factor-beta 1 and granulocyte-macrophage colony-stimulating factor.
    Hestdal K; Jacobsen SE; Ruscetti FW; Longo DL; Boone TC; Keller JR
    Exp Hematol; 1993 Jun; 21(6):799-805. PubMed ID: 8500577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
    Haas R; Hohaus S; Egerer G; Ehrhardt R; Witt B; Hunstein W
    Bone Marrow Transplant; 1992 Jun; 9(6):459-65. PubMed ID: 1352717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.
    Cannistra SA; DiCarlo J; Groshek P; Kanakura Y; Berg D; Mayer RJ; Griffin JD
    Leukemia; 1991 Mar; 5(3):230-8. PubMed ID: 1826536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemopoietic progenitor and myeloid cell kinetics in humans treated with interleukin-3 and granulocyte/macrophage colony-stimulating factor in combination.
    Lord BI; Testa NG; Bretti S; Chang J; Demuynck H; Coutinho L; de Campos E; Fitzsimmons L; Scarffe JH
    Int J Cancer; 1994 Nov; 59(4):483-90. PubMed ID: 7960217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of acetyl-n-ser-asp-lys-pro (AcSDKP) on hematopoietic progenitor cells in short-term and long-term murine bone marrow cultures.
    Jackson JD; Yan Y; Ewel C; Talmadge JE
    Exp Hematol; 1996 Feb; 24(3):475-81. PubMed ID: 8599978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.